Assessing Preferences for Rare Disease Treatment: Qualitative Development of the Paroxysmal Nocturnal Hemoglobinuria Patient Preference Questionnaire (PNH-PPQ(©))

PURPOSE: To develop a patient preference questionnaire (PPQ) assessing eculizumab and ravulizumab treatment for paroxysmal nocturnal hemoglobinuria (PNH). PATIENTS AND METHODS: The development of the PNH-PPQ(©) was consistent with Food and Drug Administration guidelines for patient-reported outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaiser, Karen, Yount, Susan E, Martens, Christa E, Webster, Kimberly A, Shaunfield, Sara, Sparling, Amy, Peipert, John Devin, Cella, David, Rottinghaus, Scott T, Donato, Bonnie M K, Wells, Richard, Tomazos, Ioannis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147619/
https://www.ncbi.nlm.nih.gov/pubmed/32308375
http://dx.doi.org/10.2147/PPA.S233830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147619/
https://www.ncbi.nlm.nih.gov/pubmed/32308375
http://dx.doi.org/10.2147/PPA.S233830

Ejemplares similares